Search

everythinglearnresearchcommunity

for

Search:↓

TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Blocking YAP/TAZ could be a new way to treat skin cancer.

Pediatric pemphigus is often diagnosed late, but rituximab helps control it long-term.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Dupilumab for atopic dermatitis can cause mild skin issues in some patients.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Omalizumab may cause temporary hair loss, especially in women aged 18-60.

Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.

Topical tofacitinib is effective and safe for treating alopecia areata.

Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

A woman with severe angioedema improved significantly after treatment with rituximab.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.